Figure 3.
Trends in disease and costa burden of CLL for the CIT and the OTT scenarios. (A) The annual prevalence of CLL (excluding patients in the watchful waiting health state) under the CIT and OTT scenarios. The use of OTT is projected to increase the number of patients living with CLL from 8301 in 2011 to 14,654 by 2025 (1.8-fold increase). (B) The total costs of CLL management per year for the CIT and OTT scenarios. The use of OTT is projected to increase the annual costs from $60.8 million in 2011 to $957.5 million in 2015 (15.7-fold increase), which is mainly driven by the increased number of patients with CLL, high drug costs and the increased duration of treatment. CIT, chemoimmunotherapy; CLL, chronic lymphocytic leukemia; OTT, oral targeted therapy. aAll costs are shown in 2019 Canadian dollars.